Trial · NCT03224585
Treatment of Acute Pericarditis With Anakinra
NCT03224585, Phase 2, Terminated, Virginia Commonwealth University; results first posted 2021-02-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Acute Pericarditis With Anakinra. Trials, record NCT03224585. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03224585
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Acute Pericarditis With Anakinra
- NCT number
- NCT03224585
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Virginia Commonwealth University
- Conditions
- Acute Pericarditis
- Interventions
- Anakinra, Placebo
- First posted
- 2017-07-21
- Last updated
- 2021-02-23
- Results first posted
- 2021-02-23
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Score | Baseline to 6 hours | Change from baseline in visual analog pain score from 0 to 10. For this visual analog pain scale, the patient is asked to rate their pain from 0 to 10. A score of 0 represents "no pain", a score of 5 represents "moderate pain", and 10 represents "worst pain". |
| Secondary | Pain Score | Baseline to 24 hours | Change from baseline in visual analog pain score from 0 to 10. For this visual analog pain scale, the patient is asked to rate their pain from 0 to 10. A score of 0 represents "no pain", a score of 5 represents "moderate pain", and 10 represents "worst pain". |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Score | Baseline to 6 hours | units on a scale | MEDIAN | |
| SECONDARY | Pain Score | Baseline to 24 hours | units on a scale | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Score | All Patients | -3 | Inter-Quartile Range -3 to -2 | units on a scale | |
| Pain Score | All Patients | -4 | Inter-Quartile Range -4.25 to 4 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Anakinra (3 Days) Then Anakinra (4 Days) | 2 | |
| Overall Study | STARTED | Anakinra (3 Days) Then Placebo (4 Days) | 3 | |
| Overall Study | COMPLETED | Anakinra (3 Days) Then Anakinra (4 Days) | 2 | |
| Overall Study | COMPLETED | Anakinra (3 Days) Then Placebo (4 Days) | 3 | |
| Overall Study | NOT COMPLETED | Anakinra (3 Days) Then Anakinra (4 Days) | 0 | |
| Overall Study | NOT COMPLETED | Anakinra (3 Days) Then Placebo (4 Days) | 0 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site reactions - While taking anakinra | Skin and subcutaneous tissue disorders | Anakinra (3 Days) Then Anakinra (4 Days) | 1 | 2 | 1 |
| other | Injection site reactions - While taking anakinra | Skin and subcutaneous tissue disorders | Anakinra (3 Days) Then Placebo (4 Days) | 1 | 3 | 1 |
| serious | Thrombophlebitis - After completion of anakinra | Vascular disorders | Anakinra (3 Days) Then Anakinra (4 Days) | 0 | 2 | 0 |
| serious | Thrombophlebitis - After completion of anakinra | Vascular disorders | Anakinra (3 Days) Then Placebo (4 Days) | 1 | 3 | 1 |
| serious | Coronary vasospasm - After completion of anakinra | Cardiac disorders | Anakinra (3 Days) Then Anakinra (4 Days) | 0 | 2 | 0 |
| serious | Coronary vasospasm - After completion of anakinra | Cardiac disorders | Anakinra (3 Days) Then Placebo (4 Days) | 1 | 3 | 1 |
| serious | Resistant pericarditis - After completion of anakinra | Cardiac disorders | Anakinra (3 Days) Then Anakinra (4 Days) | 0 | 2 | 0 |
| serious | Resistant pericarditis - After completion of anakinra | Cardiac disorders | Anakinra (3 Days) Then Placebo (4 Days) | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Anakinra (3 Days) Then Anakinra (4 Days) | 0 | 2 |
| Total, all-cause mortality | Anakinra (3 Days) Then Placebo (4 Days) | 0 | 3 |
| Total, other adverse events | Anakinra (3 Days) Then Anakinra (4 Days) | 1 | 2 |
| Total, other adverse events | Anakinra (3 Days) Then Placebo (4 Days) | 1 | 3 |
| Total, serious adverse events | Anakinra (3 Days) Then Anakinra (4 Days) | 0 | 2 |
| Total, serious adverse events | Anakinra (3 Days) Then Placebo (4 Days) | 3 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32398478 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Anakinra (3 Days) Then Anakinra (4 Days) vs Anakinra (3 Days) Then Placebo (4 Days): deaths from any cause | Trial comparisons |
| Anakinra (3 Days) Then Anakinra (4 Days) vs Anakinra (3 Days) Then Placebo (4 Days): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03224585
GET https://conductscience.org/api/trials/v1/NCT03224585/registered